Universität zu Köln

Journal Article

Awasthi, Rakesh, Pacaud, Lida, Waldron, Edward, Tam, Constantine S., Jager, Ulrich, Borchmann, Peter, Jaglowski, Samantha ORCID: 0000-0002-4335-2554, Foley, Stephen Ronan, van Besien, Koen ORCID: 0000-0002-8164-6211, Wagner-Johnston, Nina D., Kersten, Marie Jose, Schuster, Stephen J., Salles, Gilles, Maziarz, Richard T., Anak, Ozlem, del Corral, Christopher, Chu, Jufen, Gershgorin, Irina, Pruteanu-Malinici, Iulian, Chakraborty, Abhijit, Mueller, Karen Thudium and Waller, Edmund K. (2020). Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv., 4 (3). S. 560 - 573. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 2473-9537

Bishop, Michael R., Dickinson, Michael, Purtill, Duncan, Barba, Pere, Santoro, Armando, Hamad, Nada, Kato, Koji, Sureda, Anna, Greil, Richard, Thieblemont, Catherine, Morschhauser, Franck, Janz, Martin, Flinn, Ian W., Rabitsch, Werner, Kwong, Yok Lam, Kersten, Marie Jose, Minnema, Monique C., Holte, Harald, Chan, Esther Hian Li, Martinez-Lopez, Joaquin, Mueller, Antonia M. S., Maziarz, Richard T., McGuirk, Joseph P., Bachy, Emmanuel, Le Gouill, Steven, Dreyling, Martin, Harigae, Hideo, Bond, David A., Andreadis, Charalambos, McSweeney, Peter A., Kharfan-Dabaja, Mohamed A., Newsome, Simon, Degtyarev, Evgeny, Del Corral, Chris, Andreola, Giovanna, Masood, Aisha, Schuster, Stephen J., Jaeger, Ulrich, Borchmann, Peter and Westin, Jason R. (2021). Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study. Blood, 138. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fowler, Nathan Hale, Dickinson, Michael, Dreyling, Martin, Martinez-Lopez, Joaquin, Kolstad, Arne, Butler, Jason ORCID: 0000-0002-6422-4404, Ghosh, Monalisa, Popplewell, Leslie, Chavez, Julio C., Bachy, Emmanuel, Kato, Koji, Harigae, Hideo, Kersten, Marie Jose, Andreadis, Charalambos, Riedell, Peter A., Ho, P. Joy, Perez-Simon, Jose Antonio, Chen, Andy, I, Nastoupil, Loretta J., von Tresckow, Bastian, Ferreri, Andres Jose Maria, Teshima, Takanori, Patten, Piers E. M., McGuirk, Joseph P., Petzer, Andreas L., Offner, Fritz, Viardot, Andreas, Zinzani, Pier Luigi, Malladi, Ram, Zia, Aiesha, Awasthi, Rakesh, Masood, Aisha, Anak, Oezlem, Schuster, Stephen J. and Thieblemont, Catherine (2022). Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat. Med., 28 (2). S. 325 - 343. BERLIN: NATURE PORTFOLIO. ISSN 1546-170X

Schuster, Stephen J., Bishop, Michael R., Tam, Constantine, Borchmann, Peter, Jaeger, Ulrich, Waller, Edmund K., Holte, Harald, McGuirk, Joseph P., Jaglowski, Samantha, Tobinai, Kensei, Andreadis, Charalambos, Fleury, Isabelle, Mielke, Stephan, Teshima, Takanori, Westin, Jason R., Bachanova, Veronika, Foley, Stephen Ronan, Ho, P. Joy, Magenau, John M., Wagner-Johnston, Nina D., Kato, Koji, Kersten, Marie Jose, Van Besien, Koen, Chu, Jufen, Jary, Aline, Anak, Ozlem, Salles, Gilles and Maziarz, Richard Thomas T. (2018). Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Schuster, Stephen J., Tam, Constantine S., Borchmann, Peter, Worel, Nina, McGuirk, Joseph P., Holte, Harald, Waller, Edmund K., Jaglowski, Samantha, Bishop, Michael R., Damon, Lloyd E., Foley, Stephen Ronan, Westin, Jason R., Fleury, Isabelle, Ho, P. Joy, Mielke, Stephan ORCID: 0000-0002-8325-9215, Teshima, Takanori, Janakiram, Murali, Hsu, Jing-Mei, Izutsu, Koji, Kersten, Marie Jose, Ghosh, Monalisa, Wagner-Johnston, Nina, Kato, Koji, Corradini, Paolo, Martinez-Prieto, Marcela, Han, Xia, Tiwari, Ranjan, Salles, Gilles and Maziarz, Richard T. (2021). Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol., 22 (10). S. 1403 - 1416. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Sonneveld, Pieter, Salwender, Hans-Juergen, Van der Holt, Bronno, el Jarari, Laila, Bertsch, Uta, Blau, Igor W., Zweegman, Sonja, Weisel, Katja C., Vellenga, Edo, Pfreundschuh, Michael, Broijl, Annemiek, Scheid, Christof, Wittebol, Shulamiet, Bos, Gerard M. J., Stevens-Kroef, Marjan, Jauch, Anna, Potamianou, Anna, Hose, Dirk, Raymakers, Reinier, Schaafsme, Marinus, Kersten, Marie Jose, Kooy, Marinus van Marwijk, Duehrsen, Ulrich, Lindemann, Hans Walter, Brossart, Peter, Wijermans, Pierre, Lokhorst, Henk M. and Goldschmidt, Hartmut (2015). Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Thijssen, Rachel ORCID: 0000-0002-4493-306X, ter Burg, Johanna, Garrick, Brett, van Bochove, Gregor G. W., Brown, Jennifer R., Fernandes, Stacey M., Sole Rodriguez, Maria, Michot, Jean-Marie ORCID: 0000-0003-3482-3331, Hallek, Michael, Eichhorst, Barbara, Reinhardt, Hans Christian, Bendell, Johanna, Derks, Ingrid A. M., van Kampen, Roel J. W., Hege, Kristen, Kersten, Marie Jose, Trowe, Torsten, Filvaroff, Ellen H., Eldering, Eric and Kater, Arnon P. (2016). Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood, 128 (4). S. 574 - 584. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Westin, Jason, Tam, Constantine, Borchmann, Peter, Jaeger, Ulrich, McGuirk, Joseph, Holte, Harald, Waller, Edmund, Jaglowski, Samantha, Bishop, Michael, Andreadis, Charalambos, Foley, Stephen Ronan, Fleury, Isabelle, Ho, P. Joy, Mielke, Stephan, Teshima, Takanori, Schuster, Stephen, Bachanova, Veronika, Maziarz, Richard, Van Besien, Koen, Izutsu, Koji, Kersten, Marie Jose, Magenau, John, Wagner-Johnston, Nina, Kato, Koji, Corradini, Paolo, Han, Xia, Tiwari, Ranjan, Agoulnik, Sergei, Elderjou, Lamis, Pacaud, Lida Bubuteishvili and Salles, Gilles (2020). Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy iN Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. Bone Marrow Transplant., 55 (SUPPL 1). S. 48 - 52. LONDON: SPRINGERNATURE. ISSN 1476-5365